Nabriva Therapeutics (NBRV) is trading 8% higher at $3.245 today.
- Nabriva Therapeutics (NASDAQ: NBRV) stock surged in price this morning due to a 1-for-25 reverse stock split.
- This means that for every 25 shares of NBRV stock, investors will receive 1 share of stock.
- The reverse stock split was done in order to boost the price of the stock and meet minimum listing requirements.
Nabriva Therapeutics has been trading between a 52-week high of $35 and a 52-week low of $2.91. The stock has a market cap of $216 Million.
Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections. Nabriva Therapeutics received U.S. Food and Drug Administration approval for XENLETA® (lefamulin injection, lefamulin tablets), the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP). Nabriva Therapeutics is also developing CONTEPO™ (fosfomycin) for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections (cUTI), including acute pyelonephritis.